Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm, Open-label Phase 3b Study to Describe the Safety and Tolerability of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy

NCT05907057 is registered in ClinicalTrials.gov with Servier Affaires Médicales as lead sponsor.

NCT NCT05907057
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05907057 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm, Open-label Phase 3b Study to Describe the Safety and Tolerability of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy
Lead sponsor
Servier Affaires Médicales
Phase
Phase 3
Overall status
Recruiting
Start date
June 14, 2023
Completion date
October 15, 2027
Enrollment
245 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml)